

Barcelona, 13<sup>th</sup> March 2024

## **OTHER RELEVANT INFORMATION**

### **Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases**

In accordance with Securities Markets Law, Almirall S.A. (“Almirall”) announces the following:

Almirall and Eloxx Pharmaceuticals, Inc. announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.

The drug candidate is expected to shortly enter into Phase 1 development in healthy volunteers.

As part of this agreement, Eloxx will receive an upfront of \$3 million, and additional payments throughout the potential development phases, including regulatory and sales milestones of up to \$470 million, as well as tiered royalties based on any potential future global sales.

RDEB/JEB are rare skin diseases characterized by defects in the Collagen7 gene, which is essential for the correct formation of the skin structure and barrier function. ZKN-013 has demonstrated robust functional preclinical activity in RDEB/JEB patient cells and in APCmin (multiple intestinal neoplasia) mice. The studies demonstrated that ZKN-013 induces the production of functional, full-length COL7 in RDEB patient cells.

Sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)